Recent findings from Mayo Clinic researchers indicate that Wegovy (semaglutide) supported an average yearly weight loss of about 13 percent in a study population. The results were shared at a European obesity conference held in Dublin and are considered preliminary until confirmed by peer‑reviewed publication. (Source: Mayo Clinic findings presented at the European Obesity Congress.)
The investigation drew on data from 305 participants with an average age around 49 and a body mass index averaging 41, placing them in the category of morbid obesity. A year into follow‑up, complete weight data were available for 110 of these individuals. Within this subgroup, the average weight reduction reached 13.4 percent, with the magnitude of loss higher in people without diabetes (nearly 17 percent) than in those with diabetes (about 10 percent). (Source: Mayo Clinic study presentation)
Beyond weight changes, the regimen produced notable improvements in cardiovascular risk factors, including reductions in both systolic and diastolic blood pressure and in total cholesterol levels. (Source: Mayo Clinic conference data)
Wegovy is administered via a self‑injection syringe and is given on a weekly schedule. It was initially developed for diabetes management but has since been approved for adults with obesity who have at least one weight‑related health issue, aligning with broader guidelines that support its use in combination with lifestyle interventions. (Source: regulatory approvals and product labeling)
Experts caution that the medication is most effective when paired with a sustained, reduced‑calorie diet and regular physical activity. Without ongoing lifestyle changes, some weight regain can occur after stopping therapy or maintenance of reduced caloric intake. (Source: clinical guidance and research summaries)
Overall, the researchers emphasized that Wegovy has demonstrated weight loss outcomes that exceed those reported for previously approved anti‑obesity therapies in similar populations. This finding supports its continued role as part of a comprehensive obesity treatment strategy that includes diet, exercise, and medical oversight. (Source: conference commentary and subsequent analyses)